POPULARITY
Categories
193 episodes with Gene editing
94 episodes with Gene editing
21 episodes with Gene editing
10 episodes with Gene editing
17 episodes with Gene editing
11 episodes with Gene editing
6 episodes with Gene editing
5 episodes with Gene editing
11 episodes with Gene editing
5 episodes with Gene editing
11 episodes with Gene editing
6 episodes with Gene editing
11 episodes with Gene editing
6 episodes with Gene editing
14 episodes with Gene editing
5 episodes with Gene editing
5 episodes with Gene editing
3 episodes with Gene editing
9 episodes with Gene editing
7 episodes with Gene editing
7 episodes with Gene editing
5 episodes with Gene editing
6 episodes with Gene editing
5 episodes with Gene editing
5 episodes with Gene editing
4 episodes with Gene editing
8 episodes with Gene editing
8 episodes with Gene editing
3 episodes with Gene editing
6 episodes with Gene editing
3 episodes with Gene editing
8 episodes with Gene editing
7 episodes with Gene editing
6 episodes with Gene editing
5 episodes with Gene editing
5 episodes with Gene editing
4 episodes with Gene editing
2 episodes with Gene editing
5 episodes with Gene editing
2 episodes with Gene editing
3 episodes with Gene editing
2 episodes with Gene editing
7 episodes with Gene editing
5 episodes with Gene editing
5 episodes with Gene editing
5 episodes with Gene editing
2 episodes with Gene editing
2 episodes with Gene editing
3 episodes with Gene editing
73 episodes with Gene editing
4 episodes with Gene editing
4 episodes with Gene editing
3 episodes with Gene editing
3 episodes with Gene editing
"I'd already finished my cardiovascular unit. I'd finished my pulmonary unit. I had never heard about this in any of my classes." That was Dr. Joel Bervell's reaction to discovering that a device used every day in hospitals -- the pulse oximeter -- reads less accurately on darker skin tones. He posted a 30-second video about this consequential discrepancy that, to his utter surprise, gained over 500,000 views by the next morning. That video launched Dr. Bervell into orbit as a social media presence and created his identity as The Medical Mythbuster. In just a few years, he's built a following of two million people, earned a Peabody Award and was named to the inaugural Time 100 Creators list, all while finishing his residency. On this episode of Raise the Line, host Lindsey Smith welcomes Dr. Bervell to explore the roots of this kind of bias and the real world impact of drawing attention to it. “The most impactful biases in medicine exist because no one stops to ask who was included in the original data and who was left out,” Dr. Bervell explains. Stay tuned to also learn about: His YouTube animated series The Doctor is In which helps kids understand how their bodies work, as well as providing medical role models; How to build trust with marginalized communities; His forthcoming book, The Default Body which examines who medicine was actually designed for. Mentioned in this episode:Dr. Bervell on InstagramTikTok ChannelFacebook"The Doctor Is In" Show If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Topics discussed on today's show: National Banana Split Day, Heidiâs Brother the Hero, Cat Toes, New Game Show, Cushioning, Invertebrates, Horse Sales Down, New Starbucks, Hawk Fire, 49ers Prostitution, Plastic Cookies, Blind Smart App, Old Sayings, Minimalist or Lived in Home?, Pop History Quiz, Warm Temps in the US, Ellaâs Record, GTA 6 Leaks, Robot News, Robots or Aliens, Gene Editing, GLP1âs and Muscles, Good Dad Bad Dad, Weapon Kids, Dry Scooping, Once and Never Again, Beer Study, Pointless Products, and Apologies.
Have you heard about the radioactive wolves in Chernobyl? Or the latest gene-editing tech that's curing rare diseases? Or that male birth control might be on the horizon? No?!Well, get ready, because while we've been busy living our lives, genomics has been moving – fast! Things that once read like science fiction are moving on over to the non-fiction section.This season on Nice Genes!, join Dr. Kaylee Byers as she engages in some big genomics breakthroughs – from personalized cancer treatments, to how our bodies react in space, to how animals adapt to the most extreme environments, and whether we can actually change how we age.It's a whole new gene-eration (if you will) of discoveries that you won't want to miss!New episodes every two weeks, starting September 8th. Make sure you follow Nice Genes! so you don't miss an episode!
BEST OF: After our “AILIEN The Final Card” show, it became apparent that the push to grant mass “amnesty” to every person and agency involved in black budget programs was a dangerous narrative gaining more traction by the day, and now compounded by an executive order from the White House titled “Launching the Genesis Mission.” This program seeks to support, along with the AI regulation moratorium of the BBB, the narrative that “America is in a race for global technology dominance in the development of artificial intelligence (AI).” The first section states: “the challenges we face require a historic national effort, comparable in urgency and ambition to the Manhattan Project that was instrumental to our victory in World War II.” But what suddenly changed? Have other countries cracked the AI egg entirely or has, as the UFO community suggests, they reverse engineered alien tech fully? Even so, a dangerous nationwide Manhattan Project should be a secret, not a public initiative. One part of the EO says the goal is to develop "AI-enabled predictive models, simulation models, and design optimization tools,” things that have been sold to the public over and over again, from climate change to pandemic models, but which have all been wrong. But if AI says something is true based on a model, it must be correct. However, if AI is merely saying what is most likely based on current actions, like a tarot reading, then if all current policies are designed for war then isn't that what we will get? Isn't that what Alex Karp of Palantir said would happen? And isn't “Genesis” also “skynet”?For those left waiting for something “big” to happen it will be disappointing to learn that it already has. Engineered smart/micro-dust is currently turning the world into a giant sensor, while Sam Altman of the Stargate Project, OpenAI, and the Orb, is now funding CRISPR-based embryo gene editing as the alterer-of-man.And to keep us entertained during this slow-burn apocalyptic invasion, we have KION, an AI-created K-pop star who's clearly created with all he best black goo moments from Taylor Swift, Lady Gaga, Billie Eilish, and the like. It all makes sense if the gift of “UFO technology” may in fact be a series of blueprints to build the alien mind on earth; the name KION, from various languages, translates to ancient-foundation-leader-possessed. In other words, Lovecraft's Old Ones once more. But IT is being sold as a sexy black goo princess. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below.
Despite gains in recent years, Black, Hispanic, and Asian communities are still under-represented in the U.S. nursing workforce. We're going to explore that gap and how to close it on this episode of Raise the Line from Elsevier with Dr. Ernest Grant, Vice Dean for Diversity, Equity, Inclusion and Belonging at the Duke University School of Nursing. "You get a patient who is more compliant when they see someone who looks like them, who is from their culture and who can advocate on their behalf," he tells host Lindsey Smith. Dr. Grant bases that and other insights on a rich professional background that includes 50 years in nursing, being a leading advocate for his profession and breaking down barriers himself as a male nurse of color and the first man elected president of the American Nurses Association. In this thoughtful conversation, Dr. Grant reflects on what it took to earn credibility in leadership roles, how he's navigating the political climate on DEI initiatives, and the causes and solutions to the persistent shortage in nursing faculty, among other pressing issues. Tune in for a uniquely-informed look at what it will take to build a stronger, more representative nursing profession. Mentioned in this episode: Duke University School of Nursing American Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
What does it take to compete on the world's biggest stage and then pivot to one of the most demanding training paths in professional life? Today's guest, Samantha "Sammy" Kolowrat, has done both, and she has some fascinating insights into the commonalities of those two worlds on this episode of Raise the Line. “Something that really drew me to medicine is the team atmosphere that's there as you work towards a common goal, and there's this level of intensity that's very reminiscent of the experiences I had as a professional athlete.” Originally from Prague, Kolowrat represented Czechia at six IIHF Women's World Championships and the 2022 Beijing Olympics, and also captained the Division I women's hockey team at the University of Vermont while earning degrees in biology and pharmacology. As she starts an anesthesiology residency at Vanderbilt University, she credits her athletic career with shaping how she handles pressure, feedback, and teamwork in medicine. "The more I improve, the more knowledge I acquire, the more skills I hone, the better care my patients get," she tells host Lindsey Smith, describing what drew her to a field that rewards the same relentless fine-tuning as elite sports. This engaging conversation also explores: How crippling performance anxiety as a Division I athlete ended up preparing Kolowrat for the operating room; Why she was drawn to anesthesiology's "well-oiled machine" atmosphere; The mentorship gap she's working to close for the next generation of athlete-physicians. Mentioned in this episode: Vanderbilt University Anesthesiology Residency Program If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
This special episode features the Munk Debate on the Gene Editing, held before a live audience of 800 students and faculty at Deerfield Academy in April 2026.Arguing in favour of the motion was the biophysicist, best-selling author, biotechnology entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA School of Medicine, Gregory Stock. His debate partner was the internationally acclaimed strategic philosopher and pioneering transhumanist Max More. Arguing against the motion was the prominent American bioethicist Ezekiel Emanuel, Special Advisor to the Director General of the WHO and a former founding chair of the Department of Bioethics at the NIH. His debate partner wass the award-winning educator, author, and Professor of Reproductive Science at University College London, Joyce Harper.Become a Munk Donor ($50 annually) to get 72-hour advanced access to the full length editions of Friday Focus and Munk Dialogues. Go to www.munkdebates.com to sign up. Hosted on Acast. See acast.com/privacy for more information.
Send us Fan MailMost of us think of medicine as something we take every day - a statin, a blood pressure pill, or perhaps a monthly injection. But what if those lifelong treatments eventually become obsolete? What if one carefully targeted gene edit could dramatically reduce your risk of heart disease for decades? Dr. Trevor Martin, Ph.D. is the Co-Founder and Chief Executive Officer of Mammoth Biosciences ( https://mammoth.bio/ ), a pioneering biotechnology company developing next-generation CRISPR genome editing technologies for potentially curative medicines. He co-founded the company in 2017 alongside Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna and an interdisciplinary team of leading scientists with the goal of building more precise, versatile, and clinically practical gene editing systems.Dr. Martin earned his undergraduate degree in Molecular Biology with honors from Princeton University before completing a Ph.D. in Genetics and Statistics at Stanford University, where his research focused on quantitative genetics, genomics, and computational biology. His scientific background in statistics and genetics has shaped Mammoth's unique approach to developing smaller CRISPR enzymes capable of reaching tissues and diseases that have been difficult to target with first-generation technologies.Under Dr. Martin's leadership, Mammoth has grown into one of the world's leading CRISPR companies, raising more than $465 million, achieving a valuation exceeding $1 billion, and establishing strategic collaborations with companies including Vertex Pharmaceuticals, Bayer, and Regeneron Pharmaceuticals.Today, Mammoth is advancing a pipeline of in vivo gene editing therapies, including programs targeting cardiovascular disease through permanent editing of the APOC3 gene - a potential one-time treatment approach aimed at dramatically reducing triglycerides and long-term cardiovascular risk. Beyond therapeutics, the company's CRISPR platform also extends into diagnostics and genome engineering technologies that may reshape medicine over the coming decades.Dr. Martin has been recognized as an EY Entrepreneur of the Year®, Forbes 30 Under 30, and Fortune 40 Under 40 honoree for his contributions to biotechnology and scientific entrepreneurship.#CRISPR #GeneEditing #TrevorMartin #MammothBiosciences #JenniferDoudna #Biotechnology #GenomeEditing #HeartDisease #Longevity #FutureOfMedicine #PrecisionMedicine #Genetics #DNA #HealthInnovation #MedicalBreakthrough #CardiovascularDisease #SciencePodcast #Biotech #Innovation #ProgressPotentialPossibilitiesSupport the show
The scientific world was rocked last month, when the case of a six-year-old girl who died in China, surfaced. The child was believed to have Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder caused by a mutation in the CHD3 gene. The condition affects intellectual development, but its severity varies widely. The girl's parents sought an experimental treatment led by neuroscientist Zilong Qiu at the Shanghai Jiao Tong University. What happened then was the child underwent base editing therapy, a specialised form of gene editing therapy. The therapy was directed at her brain to correct a genetic mutation in her brain cells. The parents are believed to have financed much of the therapy's development. Within days of the therapy, the child developed a fever and kidney damage, and died a week later. The case has thrown up a number of issues: why was an experimental treatment such as this allowed to go forward even after animal testing had reportedly found dangerous side effects? How much treatment of this sort should be allowed when its effects are still not fully understood? Are there gaps in scientific regulatory mechanisms that need to be fixed? Should families of patients be financially supporting such treatments? And finally, what does this say about our treatment of persons with disabilities? Guest: Dr. Debojyoti Chakraborty, Senior Principal Scientist, CSIR Institute of Genomics and Integrative Biology, New Delhi Host: Zubeda Hamid Producer: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices
An 11-year-old boy in rural Zambia once told Dr. Genesis Mwamba that he was about to attend school wearing shoes for the first time in his life. That moment, Dr. Mwamba says, crystallized why he started the Lead Me Back Foundation to provide school supplies and other support to marginalized communities in his native country. As you'll learn in this inspiring installment in our NextGen Journeys series, Dr. Mwamba started the foundation in 2021while still a medical student because he had experienced the power of education as an “equalizer” in his own life, taking him from humble roots to a career in medicine. He and his colleagues have grown the bootstrapped organization to a point where it now provides hundreds of thousands of people across the country with educational access, climate education and community health clinics. “I've always been drawn to opportunities and initiatives that bring help to humankind,” he tells Raise the Line host Dr. Parsa Mohri. This episode also explores: What building "with" a community rather than "for" it looks like in practice; The storytelling strategy that attracted donors and partners; How his mother's untimely death inspired his commitment to preventive medicine. Mentioned in this episode: Lead Me Back Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Scientists are using gene editing to create hypoallergenic beagles -- dogs that people with canine allergies would be able to own and be around. Greg and Holly both found the story fascinating at first, but Inside Sources Executive Producer Andy Cupp -- who's also the proud owner of two beagles -- had some serious concerns. Turns out he's not alone; many on social media share the same worries. So what are they concerned about? Andy joins the show to discuss.
Send us Fan MailCardiologist and Clinical Researcher Dr. Michael Koren joins Eric Ross from "What the Health Just Happened" to talk about a wide range of topics. They discuss the history of clinical research in healthcare, the changing landscape of research in America and around the world, what's healthy (and what's not) in popular culture, and the emerging field of gene editing. They even talk about Dr. Koren's misadventures trying to get tickets to the FIFA World Cup!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!
This hour, Dr. Adam Brockman breaks down the health headlines actually worth your attention —including an outbreak that's now the largest of its kind on record — before turning to the health prep every family need before the school bell rings. Then, a simple, decades-old remedy makes a comeback as the Health Alternative of the Week. But the hour takes a hard turn with a Health Mystery that's sparking outrage across the medical world: a six-year-old girl, an $800,000 experimental treatment, and a death that was never supposed to see the light of day. Plus, the one habit Dr. Brockman says could change how you navigate your own health decisions for good.Health Headlines of the WeekHealth Alternative of the WeekHealth Mystery of the Week
"We have an untapped army of 200,000 PAs that really could step up and drive some change in the healthcare system if we weren't restricted,” says Dr. Jennifer Kolb, capturing her motivation for pushing to update practice regulations for physician associates that date back more than 50 years. As Chief Medical Officer and Senior Vice President of Clinical Affairs at the American Academy of Physician Associates, Dr. Kolb has been in the middle of the fight at the state and federal level to grant PAs more independence from physicians, full billing rights, and the increased ability to practice across state lines, among other changes. In this pertinent conversation with Raise the Line host Lindsey Smith, Dr. Kolb explains how these updates could help close huge gaps in access to healthcare, better manage the fight against chronic diseases and improve patient outcomes. Dr. Kolb also addresses: Why the name shift from "assistant" to "associate" took her years to fully appreciate; How a 10-year gap in life expectancy across Chicago zip codes shapes her view of health equity; Why PA's shouldn't wait for permission to start making change in their communities. Mentioned in this episode:American Academy of Physician Associates If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Science is conquering diseases—now breakthroughs in gene editing promise to vanquish aging itself; The healing potential of hydrogen; Attending concerts, museums and movies may help keep your body younger; Dr. Jeffrey Bland dishes on the benefits of a new full-spectrum fish oil, Omega-3 Rejuvenate.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show
First up on the podcast, freelance science journalist Brendan Borrell talks about his work reporting on the previously undisclosed death of a 6-year-old girl in a gene-editing clinical trial in China and the reasons her parents came forward. This story was produced in collaboration with Retraction Watch and supported by the Science Fund for Investigative Reporting. Next on the show, Producer Meagan Cantwell talks with Evan McKenzie, a researcher at the University of British Columbia, about an insect that evolved to avoid predators by modifying its respiratory system to withstand high pressure at depth. This week's episode was produced with help from Podigy. Image credit: Daria Lada Learn more about your ad choices. Visit megaphone.fm/adchoices
Most adults who smoke want to quit, and about half try to do so in any given year, yet fewer than one in ten succeed. That persistent gap between intention and outcome is one of the central challenges in public health, and it's exactly the kind of problem that calls for new thinking about how to communicate with people to support behavior change. Dr. Amanda Graham has been a leading force in doing just that in her role as chief health officer at Truth Initiative, the nation's largest non-profit public health organization dedicated to preventing addiction among young people and helping people of all ages to quit tobacco. On this episode of Raise the Line from Elsevier, Dr. Graham, who holds a PhD in clinical health psychology and has done 25 years of NIH-funded research focused on technology-based cessation interventions, helps us understand the interplay between behavioral science and digital communications in the field. "A well-timed message can really be powerful in interrupting what for many people is kind of an automatic behavior, especially via text, which data tell us is an extraordinarily powerful modality,” she explains to host Lindsey Smith. Tune-in to understand where the field is heading, and to learn about: Why "push" technology may work better than apps and websites when it comes to breaking automatic behaviors; How the rise of e-cigarettes, nicotine pouches, and heated tobacco has scrambled decades of public health messaging; How highschool smoking rates plunged from over 30% to less than 2%. Mentioned in this episode: Truth Initiative Program with Mayo Clinic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
First up on the podcast, freelance science journalist Brendan Borrell talks about his work reporting on the previously undisclosed death of a 6-year-old girl in a gene-editing clinical trial in China and the reasons her parents came forward. This story was produced in collaboration with Retraction Watch and supported by the Science Fund for Investigative Reporting. Next on the show, Producer Meagan Cantwell talks with Evan McKenzie, a researcher at the University of British Columbia, about an insect that evolved to avoid predators by modifying its respiratory system to withstand high pressure at depth. This week's episode was produced with help from Podigy. Image credit: Daria Lada Learn more about your ad choices. Visit megaphone.fm/adchoices
"I always remember feeling like I was part of the clean plate club," says Dr. Christle Guevarra, recalling a childhood spent quietly convinced that her weight was a matter of willpower. That belief followed her through a competitive powerlifting career and medical practice until she finally tried a GLP-1 medication herself and, as she describes it, the constant mental noise around food quieted down. Now a board-certified family and sports medicine physician, traveling team doctor for U.S. Figure Skating, and author of The Beginner's Guide to GLP-1s, Dr. Guevarra brings a rare combination of clinical authority and lived experience to the conversation around obesity medicine. In this episode of Raise the Line from Elsevier, host Lindsey Smith talks with her about what's actually changed in how physicians understand the issue and what it means for patients. "The biggest thing is reframing how we approach weight loss. It's not just a willpower problem, it is a neurobiological problem." Tune in to learn about: Why she said no to a GLP-1 prescription for two years and what finally changed her mind; The real story behind concerns about muscle loss on these medications; What happens when the “food noise" goes silent and a new set of challenges takes its place. Mentioned in this episode: Dr. Christle's website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Recorded on site at the ASGCT 2026 Annual Meeting in Boston, host Sanjay D’Souza, PhD, talks with Fyodor Urnov, PhD, about the evolution and future of gene editing. One of the 2026 ASGCT Catalyst Award co-recipients, Dr. Urnov, talks about his work in gene editing and discusses the need for collaboration in the field to bring more cell and gene therapies to patients. Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
What is the current state of gene editing for crops in the world and how could they address critical food security challenges? In this final episode of the season, we learn about the latest innovations in this new breakthrough area of plant breeding. Plus, we hear how various countries are enacting policies for gene editing, including Europe, which recently became the newest region to adopt these advanced breeding techniques. In this episode, host Laura Rosbrow-Telem talks to a range of plant breeding experts, including Euroseeds advisor Petra Jorasch about the new gene editing law in Europe. Then she speaks with Eyal Maori, Co-Founder and CTO of Tropic, about their newly released non-browning banana, and Prof. Simona Radutoiu, Co-Director of the ENSA (Enabling Nutrient Symbioses for Agriculture) research program, about how ENSA's research could reduce the need for synthetic fertilizers. Finally, Nandini Krishnamurthy, Biotechnology Portfolio Leader - External Technologies and Innovation Ecosystems at Corteva, shares how a public-private partnership harnesses the latest innovations to tackle a rampant maize disease in East Africa. State of Seed is a show from the International Seed Federation, with production services by FP Studios.
In this episode of Denatured, you'll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJack Crawford, CEO, DemeetraMagnus Gustafsson, Chief Commercial Officer, NorthX BiologicsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Millions of Americans were saddened and outraged by the Sandy Hook Elementary shooting in 2012 that took the lives of twenty children and six adults, and were left feeling helpless about the epidemic of gun violence in the U.S. that, sadly, continues to this day. But for our guest today, Shannon Watts, her feelings of devastation about the shooting turned to rage and fueled her unlikely rise to leading Moms Demand Action, which she grew into one of the largest grassroots organizations in the country, mobilizing millions of volunteers to push for stronger gun safety laws. “I wanted to stand shoulder to shoulder with a badass army of women because that's who gets things done in this country,” she says. In this inspiring conversation with Raise the Line host Michael Carrese, Watts pulls back the curtain on how the group achieved its successes and the philosophy of "losing forward" that kept volunteers showing up year after year. In her recent book Fired Up, Watts describes how she is bringing insights from that experience to a new mission: helping women identify their values, abilities, and desires and acting on them without waiting until everything is perfect. Tune-in to learn about: The "false fires" women mistake for passion; Why losing estrogen and testosterone in midlife might actually make women braver, not less so; The one exercise she does with every woman she coaches. Mentioned in this episode: Fired Up book Moms Demand Action If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Dr. Hoffman continues his conversation with physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence.”
AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.
Today on the Casual Cattle Conversations podcast, Shaye Wanner talks with ag tech consultants Chelsea Good (Good & Associates) and Jared Wareham (Horizon Venture Management) about how cow-calf producers can decide which technologies are worth adopting. They stress that many tools enter agriculture from outside the industry and may be “solutions looking for a problem,” so ranchers should evaluate technology like a toolbox and demand ROI, especially in an asset-rich, cash-poor business. Examples include mismatched expensive tags for sale barns versus value-based traceability programs, strategic uses of GPS and estrus-detection tags (often for herd bulls or specific heifer programs), virtual fencing's geography-dependent economics, and emerging biometrics, camera applications, and gene-edited pest control. They also discuss digital recordkeeping and payment systems as adoption challenges without policy drivers, and encourage producers to share pain points and explore tech that supports long-term generational sustainability. Catch more conversations like this one and learn more at https://www.casualcattleconversations.com/ Learn more about Chelsea and Good & Associates here: https://www.goodandassoc.com/ Learn more about Jared and Horizon Venture Management here: https://www.horizonventuremanagement.com/ 00:00 Tech That Pays Off 01:09 Meet Chelsea and Jared 04:40 Picking Tech by ROI 09:50 AI Is Not Magic 11:50 Genomics Fit and Value 14:39 Virtual Fencing Reality 17:09 Smart Tags and GPS 28:14 Cameras and Computer Vision 37:40 Gene Editing and Pests 43:17 Digital Records and Payments
Many scientists believe we're in the midst of a sixth mass extinction brought on by factors like climate change, deforestation, fishing and hunting. The Texas-based company Colossal Biosciences claims its technology could help prevent some of those losses, and even bring back long-extinct species. For the new season of the Marketplace climate podcast, “How We Survive,” host Amy Scott got a virtual tour of their labs.
Many scientists believe we're in the midst of a sixth mass extinction brought on by factors like climate change, deforestation, fishing and hunting. The Texas-based company Colossal Biosciences claims its technology could help prevent some of those losses, and even bring back long-extinct species. For the new season of the Marketplace climate podcast, “How We Survive,” host Amy Scott got a virtual tour of their labs.
In the United States, nearly 70% of people say they want to die at home, yet the majority still die in medical settings, often after receiving care that may not match their goals and values. Closing that gap between preference and reality is at the heart of the work being done by End Well, a nonprofit dedicated to transforming how we think about, plan for, and experience the end of life. "The gap isn't about people wanting the wrong things. It's that our culture and our incentives aren't aligned with helping those wishes actually happen at the end of life,” says Dr. Shoshana Ungerleider, End Well's founder and president. As Dr. Ungerleider explains to Raise the Line host Michael Carrese, End Well sponsors an annual symposium and year-round activities to bring together clinicians, patients, caregivers, and innovators to improve that alignment. Key steps include earlier integration of palliative care, allowing providers time for listening and goal setting with patients, and normalizing conversations about what matters most to people. This compelling conversation on reframing end of life care also covers how to bring wonder, joy, and hope into end-of-life conversations, and End Well's work to change how death is portrayed in the media. Mentioned in this episode:End Well If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Jenny Kleeman investigates ‘Biotech Barbie' Cathy Tie, the controversial entrepreneur hoping to revolutionise human reproduction by letting parents edit their embryos. Help support our independent journalism at theguardian.com/infocus
While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed. “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work. It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
He carried two copies of ApoE4, the highest genetic risk factor for Alzheimer's disease, went through medical school knowing exactly what his LDL of 700 meant, decided the experts were wrong, and then published the case report to prove it. In this episode, Louisa sits down with Dr. Nick Norwitz, PhD researcher and metabolic scientist, for one of the most scientifically dense conversations on brain health, cholesterol biology, and Alzheimer's prevention ever recorded on this show. They cover why the phospholipid form of DHA reaches the brain more effectively than standard fish oil, how ApoE4 carriers burn through omega-3s differently and what to do about it, the lithium orotate data that sold out supplement shelves worldwide, and why GSK-3 beta, the enzyme that phosphorylates tau, may be the most under appreciated target in Alzheimer's research today. Then Dr. Nick Norwitz lays out the case that challenges the "LDL is always the enemy" consensus: why metabolically healthy individuals may not benefit from aggressive lipid-lowering therapy, what his viral coronary CT angiogram showed after seven years of 700+ cholesterol, why the EZPAVE trial headlines don't hold up under scrutiny, and what GLP-1s are doing inside the brain completely independent of weight loss. You'll also hear about the sardine diet experiment, the omega-3 thermogenesis connection, ketones as misfolded protein clearance agents, creatine for depression, retatrutide and PCSK9, BPC-157 risks, and what Dr. Nick Norwitz believes is coming in Alzheimer's gene therapy within the next decade. *Reduce your risk of Alzheimer's with my science-backed protocol for women 30+:*https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ *TOPICS DISCUSSED*(00:00:00) Intro: The ApoE4 Paradox and the Case Report That Broke the Internet (00:00:57) Why Standard Omega-3 Supplements Fail and What to Take Instead (00:05:13) DHA and the Phospholipid Carrier: How It Crosses the Blood-Brain Barrier (00:10:19) ApoE4 Explained: Risk, Genetics, and Why Nick Is Optimistic (00:17:38) Why ApoE4 Carriers Burn Through DHA Faster and Need More (00:20:31) Women, Omega-3s, Menopause, and Brain Insulin Resistance (00:21:41) Statins, Sex Differences, and the DHA-Blood Sugar Connection (00:26:01) Statins and Dementia: What the Data Actually Say (00:32:24) Tau, GSK-3 Beta, Lithium Orotate, and Targeting Alzheimer's Pathology (00:42:19) The Glymphatic System, 40Hz Devices, and Sleep as Brain Clearance (00:45:21) Gene Editing, Prime Editing, and the Future of ApoE4 Therapy (00:49:33) Nick's Case Report: 700 LDL, Zero Plaque, and Seven Years of Data (00:55:10) The EZPAVE Trial: Why the Headlines Don't Hold Up (01:00:33) KetoneIQ: Ketones for Brain Energy and Focus (01:01:29) Cheers Health: Supporting Liver Function and Cognitive Recovery (01:03:54) If Not LDL, What Causes Heart Disease in Metabolically Healthy People? (01:12:05) The Oreo Experiment and the Sardine Diet: Self-Experiments in Metabolism (01:19:10) Ketones, Women's Brains, and Clearing Misfolded Proteins (01:21:08) The Full Brain Health Protocol: Omega-3s, Creatine, NAD, Lithium, and More (01:24:01) GLP-1s for the Brain: Independent of Weight, Targeting Amyloid and Tau (01:25:28) Peptides: BPC-157 Risks, Retatrutide, MOTS-c, and What's Worth Watching (01:29:02) Why Nick Is Controversial And Why He Doesn't Mind _______ *Thank you to our sponsors*Fenix Health Science: fenixhealthscience.com Use code NEUROEXPPulsetto: https://pulsetto.tech/pages/NEURO or use Code NEURO for some off your orderFunction Health: https://www.functionhealth.com/louisanicolaBASED Bodyworks: https://basedbodyworks.com/ and use code NEURO for 20% offKetoneIQ: https://ketone.com/NEURO for 30% OFFCheers Health: https://CheersHealth.com/NEURO or use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention.If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0Instagram: https://www.instagram.com/louisanicola_/Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices
He carried two copies of ApoE4, the highest genetic risk factor for Alzheimer's disease, went through medical school knowing exactly what his LDL of 700 meant, decided the experts were wrong, and then published the case report to prove it. In this episode, Louisa sits down with Dr. Nick Norwitz, PhD researcher and metabolic scientist, for one of the most scientifically dense conversations on brain health, cholesterol biology, and Alzheimer's prevention ever recorded on this show. They cover why the phospholipid form of DHA reaches the brain more effectively than standard fish oil, how ApoE4 carriers burn through omega-3s differently and what to do about it, the lithium orotate data that sold out supplement shelves worldwide, and why GSK-3 beta, the enzyme that phosphorylates tau, may be the most under appreciated target in Alzheimer's research today. Then Nick lays out the case that challenges the "LDL is always the enemy" consensus: why metabolically healthy individuals may not benefit from aggressive lipid-lowering therapy, what his viral coronary CT angiogram showed after seven years of 700+ cholesterol, why the EZPAVE trial headlines don't hold up under scrutiny, and what GLP-1s are doing inside the brain completely independent of weight loss. You'll also hear about the sardine diet experiment, the omega-3 thermogenesis connection, ketones as misfolded protein clearance agents, creatine for depression, retatrutide and PCSK9, BPC-157 risks, and what Nick believes is coming in Alzheimer's gene therapy within the next decade. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+:https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Intro: The ApoE4 Paradox and the Case Report That Broke the Internet 00:57 Why Standard Omega-3 Supplements Fail and What to Take Instead 05:13 DHA and the Phospholipid Carrier: How It Crosses the Blood-Brain Barrier 10:19 ApoE4 Explained: Risk, Genetics, and Why Nick Is Optimistic 17:38 Why ApoE4 Carriers Burn Through DHA Faster and Need More 20:31 Women, Omega-3s, Menopause, and Brain Insulin Resistance 21:41 Statins, Sex Differences, and the DHA-Blood Sugar Connection 26:01 Statins and Dementia: What the Data Actually Say 32:24 Tau, GSK-3 Beta, Lithium Orotate, and Targeting Alzheimer's Pathology 42:19 The Glymphatic System, 40Hz Devices, and Sleep as Brain Clearance 45:21 Gene Editing, Prime Editing, and the Future of ApoE4 Therapy 49:33 Nick's Case Report: 700 LDL, Zero Plaque, and Seven Years of Data 55:10 The EZPAVE Trial: Why the Headlines Don't Hold Up 01:00:33 KetoneIQ: Ketones for Brain Energy and Focus 01:01:29 Cheers Health: Supporting Liver Function and Cognitive Recovery 01:03:54 If Not LDL, What Causes Heart Disease in Metabolically Healthy People? 01:12:05 The Oreo Experiment and the Sardine Diet: Self-Experiments in Metabolism 01:19:10 Ketones, Women's Brains, and Clearing Misfolded Proteins 01:21:08 The Full Brain Health Protocol: Omega-3s, Creatine, NAD, Lithium, and More 01:24:01 GLP-1s for the Brain: Independent of Weight, Targeting Amyloid and Tau 01:25:28 Peptides: BPC-157 Risks, Retatrutide, MOTS-c, and What's Worth Watching 01:29:02 Why Nick Is Controversial And Why He Doesn't Mind _______ Thank you to our sponsors Fenix Health Science: fenixhealthscience.com Use code NEUROEXP Pulsetto: https://pulsetto.tech/pages/NEURO or use Code NEURO for some off your order Function Health: https://www.functionhealth.com/louisanicola BASED Bodyworks: https://basedbodyworks.com/ and use code NEURO for 20% off KetoneIQ: https://ketone.com/NEURO for 30% OFF Cheers Health: https://CheersHealth.com/NEURO or use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices
It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists. We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Sen Lee of Utah took exception with the Pentagon's labelling. NYT announces a new era of gene editing. John talks to Professor Robbie George about Fidelity Month. HelloFresh promotes perversion, A YouTuber is criticized for aborting a preborn baby diagnosed with Down Syndrome, but Bethany Christian Services makes a welcome change. Segment 1 – Are Mormons Christian? Gene Editing is Back Breakpoint article NY Times article on gene editing Andrew Walker article Segment 2 – Fidelity Month Fidelity Month website Segment 3 – YouTuber Kills Preborn Baby after Down Syndrome Diagnosis YouTuber article Spectator Hello Fresh article Bethany Christian Services statement Resolve Conflict and Find Peace and Hope with Adult Children: Strategies and Conversations That Work by Kathy Koch
Peter Singer critiques the Pope on Human Dignity: Scott and Erik discuss philosopher Peter Singer's reaction to the Pope's recent encyclical, analyzing how a purely functional definition of human value leads to terrifying ethical conclusions. The Neurobiology of Fatherhood: Discussing a recent New York Times piece, Scott and Erik break down the scientific evidence showing how active fatherhood positively rewires and protects a man's brain as he ages. Gene Editing and the Genetic Caste System: Analyzing a recent article on "base editing" technologies, the hosts explore the bioethical boundaries between curing diseases and pursuing human enhancements that threaten to create a permanent disparity between medical haves and have-nots.Gen Z Men Resisting Temptation: Highlighting an encouraging cultural trend reported in an article, the hosts discuss how young Gen Z men are actively navigating and resisting the omnipresent temptation to sexual sin enabled by modern technology through the power of community and fellowship. Audience Question: Is it Acceptable to Listen to AI-Generated Worship Music? A listener asks if it is morally or spiritually compromising to listen to classic, human-written hymns that are fully performed by AI voices and instruments. Applying Biblical Accountability (1 Corinthians 5) at Home: The hosts offer nuanced advice to a listener navigating how to handle the apostle Paul's strict instructions regarding unrepentant believers when that person is an immediate family member living under the same roof. What Alternative Careers Would the Hosts Choose? In a light-hearted closing segment, ethicist Scott Rae and theologian Erik Thoennes share what completely different career paths they might have pursued—such as athletics or screen printing—if they hadn't entered academia and ministry.==========Think Biblically: Conversations on Faith and Culture is a podcast from Talbot School of Theology at Biola University, which offers degrees both online and on campus in Southern California. Find all episodes of Think Biblically at: https://www.biola.edu/think-biblically. To submit comments, ask questions, or make suggestions on issues you'd like us to cover or guests you'd like us to have on the podcast, email us at thinkbiblically@biola.edu.
One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.
"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South. On this episode of Raise the Line from Elsevier, Bussey provides illuminating examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most. Mentioned in this episode: Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Topics discussed on today's show: National Call Your Doctor Day, Animal News, Mr Potato Head Record, Lab Rats, Gene Editing, Chicken Yeast, Siri, Flying Cars, Masturbating Birds, Science News: Cosmic Wind, Sea Squirts, Leaf, Bird Call, Pop History Quiz, Probably White, Gay Bars and Fart Jars, Vacations, Adam Carolla stops by the show, and Apologies.
We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple | Spotify | YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn
As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career. “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.” He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.” Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap
Can today's technology really prevent tomorrow's diseases? Today, we're talking to Eriona Hysolli, biologist and co-founder of Manhattan Genomics. We discuss why preventing genetic disease before birth is a more powerful idea than treating it in adulthood, how the UK quietly pioneered a procedure that most of the world still considers off-limits, why the loudest opposition to gene editing often comes from bioethicists rather than the public, and what it would actually take to engineer traits — from woolly mouse hair to human limb regeneration — with enough certainty to act on. To learn more about Eriona, connect with her on LinkedIn.
May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co
We love to hear from our listeners. Send us a message.This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy. They cover the broader challenges facing in vivo gene editing, including delivery limitations outside the liver, balancing specificity and efficiency, mitigating off-target risks, and translating promising preclinical in vivo data into clinical success.Subscribe to the podcast!Apple | Spotify | YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn
Topics discussed on today's show: Memorial Day Weekend, Cause of Death for Kyle Busch, Heidi's AC, Music News, Space X Rocket, Gene Editing for Heart Disease, Death, Electric Ferrari, Growing Fruits and Veggies, AI Open Rolls, Encounters with Nature, Fry Spit, Old Age and Health, Millennial Retirement Gap Year, AI Doctors and Juries, AI or..., New Shopping Cart, Special Guest Grant, Pop History Quiz, and Apologies.
The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries. On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
What are the true limits of life, will we even recognize it when we see it? Neil deGrasse Tyson and comic co-host Chuck Nice explore the beginnings of life on Earth and what they might tell us about life everywhere else with astrobiologist and bacteriologist, Betül Kaçar. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/how-did-life-begin-with-betul-kacar/ Thanks to our Patrons Christian Payne, Gage Ewing, Ryan Whynot, Temirlan, 2 Lives Left, Chad Keeler, Harli Shae Smith, Brad Smith, Norm Bailey, James Peterson, Ryan Coppens, David Whittenberg, Scott Jarboe, Varun Krishnan, Eric Salinas, Mary Seman, Melissa Davis, Stephen Rockwell, Catrina, Max Wilburn, Keith Koenigsberg, LEIII, Vincent Loniello, Simon Toth, DoctorWaterGod, Ruthanne Nava, Martineau Alex, Matthew, Phil, Jaden, Arik Drori, Papersneaker, Steven Peeters, Trey Durango, Julianne, Robbie James, Jason Foreman, Liam, Steven Van Vleet, Marilyn, Zakk Why, Ben Wheeldon, Erik Leazure, Konal Sharma, Dušan Živanović, Erik Strandberg, Berklie Novak-Stolz, Kazi Mahin Mahfuz, Tim Van Devender, Andrew Martin, Jason F, Charles Joubert, Youcef Kazwiny, Joy Joslyn, Freeman, Jessica, Pat, Phillip Brooks, Michael Hues, Jacqueline Sinclair, Robert Marsh, Botas, Raza Naqvi (Sid), Jake, Christine Bartholomew & Family, Mr Xoot, Dyonté Houston, Daryl, Rob Weiss, Caleb Holmes, Jeffrey Luce, Kellie Owczarczak, Brandt Reppond, Joseph Savage, Grace Smith, Joe Pacillo, Gregory Wright, Eric Brothwell, IvanM, Pattie Particle, Cory Fenstermaker, James H Lawson, Embreebane, Dai Stiho, Raymond C King, J M, Alex Wheeler, Jason Rushmore, Idris, Damian Correa, Dylan Woody, Julia Nolen, Chris Petit, Anna, David Kapner, Lalo, Vic, Ash Anthony, and Wayne Stubblefield for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Your doctor tells you that, should you wish to have a child, that child is likely also to carry the disease. But a new gene-editing technology could ensure that your baby is -- and remains -- healthy. Should you do it? Critics say the technology will exacerbate inequality and meddle in the most basic aspect of our humanity. Now, we debate: Should We Use Gene Editing to Make Better Babies? This ethical conundrum is at the crux of this week's debate, originally broadcast in February 2022. Arguing Yes: Dr. George Church, Geneticist & Founder, Personal Genome Project; Professor, Genetics, Wyss Institute and Harvard Medical School Amy Webb, Chief Executive Officer, Future Today Strategy Group; Professor, NYU Stern School of Business Arguing No: Marcy Darnovsky, Executive Director, Emerita, Center for Genetics and Society Françoise Baylis, Distinguished Research Professor, Emerita, Dalhousie University; President, Royal Society of Canada Emmy award-winning journalist John Donvan moderates Join the conversation on Substack - share your perspective on this episode and subscribe to our weekly newsletter for curated insights from our debaters, moderators, and staff. Follow us on YouTube, Instagram, LinkedIn, X, Facebook, and TikTok to stay connected with our mission and ongoing debates. Learn more about your ad choices. Visit podcastchoices.com/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
